Starpharma Holdings Ltd has released a press release.
Response to ASX Aware Letter
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel condom receives final regulatory approval in Japan
- US FDA requests further data for VivaGel BV approval
- US VivaGel BV licensed for A$142M milestones plus royalties
- DEP products outperform in human pancreatic cancer model
- Starpharma Investor Presentation for Citi Conference
Later from Starpharma
- Interim Report and Half-Yearly Financial Results
- Starpharma receives $4.0M R&D tax incentive refund
- First VivaGel BV launch globally in Australia by Aspen
- DEP irinotecan combination outperforms in colon cancel model
- Starpharma signs second oncology agreement with AstraZeneca
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma